<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976374</url>
  </required_header>
  <id_info>
    <org_study_id>AP2105-50105</org_study_id>
    <nct_id>NCT04976374</nct_id>
  </id_info>
  <brief_title>Analgesic Protocol With Gabapentin Dexmedetomidine For Postoperative Pain Managment</brief_title>
  <official_title>A Multimodal Analgesic Protocol With Gabapentin Dexmedetomidine For Postoperative Pain Managment After Modified Radical Mastectomy Surgery: A Randomized Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of quality of post mastectomy analgesic protocol of Gabapentin and Dexmedetomedine&#xD;
      in a placebo-controlled study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of quality of post mastectomy analgesic protocol of Gabapentin and Dexmedetomedine&#xD;
      in a placebo-controlled study.&#xD;
&#xD;
      Dexmedetomidine is a highly selective X2 adrenergic receptor aganist; it has anxiolytic,&#xD;
      sedative, analgesic and sympathdytic properties without significant respiratory depressant&#xD;
      effects. Research evidence has shown that this drug protects the body (including heart,&#xD;
      nerves, etc.) against ischemia and hypoxic injury. Therefore, dexmedetomidine can be one of&#xD;
      the best options for reducing pain after surgery.&#xD;
&#xD;
      Gabapentin, a structural analog of gamma aminobutyric acid, is used as an anticonvulsant drug&#xD;
      since 1993. In addition it has been effective in neuropathic pain, diabetic neuropathy and&#xD;
      reflex sympathetic dystrophy. It acts through binding to the X-2-5 subvnits of voltagegated&#xD;
      calcium ion channels and preventing the central sentization and hyperalgesia. Gabapentin has&#xD;
      demonstrated to inhibit the development and establishment of hyperalgesia and secondry&#xD;
      allodynia in human volunteers.&#xD;
&#xD;
      Gabapentin may also decrease postoperative obioid requirement through preventing the&#xD;
      tolerance development. Furthermore, it has minimal or no effect on gastric mucosa, renal&#xD;
      function, and platelets count or activity in the perioperative period to be prefer over&#xD;
      nonsteroidal anti-inflammatory drugs.&#xD;
&#xD;
      The Combination of both drugs will be tested for potentiation of post-operative analgesia and&#xD;
      decrease of opioid consumptions&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">November 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post operative morphine consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Evaluation of the effects of combining and gabapentin and dexmedetomidine infusion on post operative morphine consumption within the first 24 h in patients undergoing modified radical mastectomy surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post operative VAS score</measure>
    <time_frame>24 hours</time_frame>
    <description>Evaluation of the effects of combining and gabapentin and dexmedtomidine infusion on post operative visual analogue scale (VAS) score within the first 24 h in patients undergoing modified radical mastectomy surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients of group A will start dexmedetomidine (precedex 100 ug lmL, Hospira) infusion 0.4 ug {Kg}h after bolus of 0.5 ug 1 kg intravenously over 10 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B will recive a bolus of saline then saline infusion identical to group A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine and Gabapentin</intervention_name>
    <description>Administration of intravenous dexmedetomedine for post operative analgesic purposes in combination with gabapentin</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>gabapentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intravenous Saline 0.9% for placebo purposes</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult female patients below 65 years of age scheduled for modified radical mastectomy&#xD;
             surgery, American society of Anesthesiologists(ASA) physical status I-II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known allergy to study drugs; patients already taking oral gabapentin, knal or hepatic&#xD;
             defunction, current treatment with narcotics, antihypertensives, benzodiazepines, X2&#xD;
             agonists, antiepileptics and antipsychotics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ahmed hu bakir, MD</last_name>
    <phone>01115661922</phone>
    <email>ahmed_bakir77@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nasr ma Abdullah, MD</last_name>
    <phone>01005223734</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NCI Egypt</name>
      <address>
        <city>Cairo</city>
        <zip>02002</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed H. Bakir, M.D</last_name>
      <phone>01115661922</phone>
      <email>ahmed_bakir77@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>October 31, 2021</last_update_submitted>
  <last_update_submitted_qc>October 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Ahmed Bakir</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesia, Intensive care and Pain Relief</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Study protocol, methodology and results to be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

